J&J faces first UK lawsuits alleging its baby powder caused cancer

Johnson & Johnson and its former consumer health unit Kenvue are now facing their first lawsuits in Britain, with over 3,000 claimants alleging their talc products caused cancer, a suit estimated at £1 billion ($1.34 billion). This expands J&J's extensive U.S. talc litigation, which includes tens of thousands of cases and a recent $966 million award, despite both companies maintaining their products are safe and asbestos-free. The British legal system, which typically limits damages to compensation and uses judge-led trials, presents a different risk profile compared to the U.S. system's potential for large punitive awards and jury trials.

Analysis

The initiation of the first talc-related lawsuits in Britain against Johnson & Johnson (JNJ) and its former consumer health unit, Kenvue (KVUE), significantly expands the companies' legal challenges. Over 3,000 claimants allege their use of J&J's baby powder between 1965 and 2023 caused ovarian cancer or mesothelioma due to carcinogenic fibers, including asbestos, with the suit estimated at £1 billion ($1.34 billion). Both J&J and Kenvue vehemently deny these allegations, asserting their products are safe and asbestos-free.

This new front adds to tens of thousands of similar U.S. lawsuits, where J&J recently faced a $966 million award, including $950 million in punitive damages. However, the British legal system presents a different risk profile, typically limiting damages to compensation for losses and featuring judge-led trials, contrasting with the U.S. system's potential for substantial punitive awards and jury verdicts. J&J's previous attempts to resolve U.S. litigation through bankruptcy have been rejected three times.

The liability allocation post-Kenvue's 2023 spin-off is a critical factor, with J&J stating Kenvue "retained the responsibility and any purported liability for talc-related litigation outside of the United States and Canada." This suggests Kenvue may bear the primary financial burden for the UK cases, although J&J's overall brand reputation remains intertwined. The strongly negative sentiment for both JNJ (-0.9) and KVUE (-0.8) reflects the market's concern over these protracted legal battles.

Key Decisions for Investors

• Monitor the progression and outcomes of the UK talc litigation, specifically observing how the judge-led process and limited punitive damages impact financial liabilities compared to U.S. precedents.
• Evaluate the clarity and enforceability of the liability transfer agreement between JNJ and KVUE for international talc claims, as this will dictate each entity's direct financial exposure.
• Assess the cumulative impact of ongoing global litigation on both companies' long-term brand equity and consumer trust, considering potential shifts in market perception and regulatory scrutiny.